Article
IBI112, a selective anti-IL23p19 monoclonal antibody, displays high efficacy in IL-23-induced psoriasiform dermatitis.
International immunopharmacology - 1 Dec 2020
Li Li, Wu Zhihai, Wu Min, Qiu Xuan, Wu Yue, Kuang Zhihui, Wang Li, Sun Ta, Liu Yang, Yi Shuai, Jing Hua, Zhou Shuaixiang, Chen Bingliang, Wu Dongdong, Wu Weiwei, Liu Junjian
Abstract excerpt
Psoriasis is a highly prevalent inflammatory skin disease. Plaque psoriasis is the most common type of psoriasis, and the interleukin (IL)-23/IL-17 axis plays a key role in disease progression. In this article, we describe IBI112, a highly potent anti-IL-23 monoclonal antibody under clinical development, which efficiently neutralizes IL23p19, a subunit of IL-23, to abrogate IL-23 binding to its receptor and block...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.